Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 9/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18608362 | 0.71 | IDO1 (0.46) | IDO1KDM4ETSHRHSD17B10ALDH1A1 | |
| SCHEMBL7331667 | 0.67 | RAB9A (0.52) | KDM4EHSD17B10ALDH1A1L3MBTL1MAPT | |
| SCHEMBL4769711 | 0.67 | EGFR (0.41) | KDM4EHSD17B10ALDH1A1MAPT | |
| SCHEMBL10984214 | 0.66 | IDO1 (0.40) | IDO1KDM4ETSHRHSD17B10BRD4 | |
| SCHEMBL567443 | 0.66 | IDO1 (0.71) | IDO1KDM4ETSHRHSD17B10BRD4 | |
| SCHEMBL14814883 | 0.65 | BRD4 (0.65) | IDO1KDM4ETSHRHSD17B10BRD4 | |
| SCHEMBL14814610 | 0.65 | BRD4 (0.60) | IDO1KDM4ETSHRHSD17B10BRD4 | |
| SCHEMBL14814790 | 0.65 | BRD4 (0.60) | IDO1KDM4ETSHRHSD17B10BRD4 | |
| SCHEMBL474103 | 0.64 | HPGDS (0.51) | KDM4EHSD17B10ALDH1A1MAPT | |
| SCHEMBL14814497 | 0.64 | BRD4 (0.71) | IDO1KDM4ETSHRHSD17B10BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1575963-B1 | ANTI-ANGIOGENETIC THERAPEUTIC AGENTS | ASTRAZENECA AB (SE) | 2008-05-07 | — | — | EP | disclosed |
| US-20060069109-A1 | Therapeutic agents | ASTRAZENECA AB (SE) | 2006-03-30 | — | — | US | disclosed |
| EP-1575963-A1 | THERAPEUTIC AGENTS | AstraZeneca AB (SE) | 2005-09-21 | — | — | EP | disclosed |
| WO-2004058776-A1 | THERAPEUTIC AGENTS | ASTRAZENECA AB (SE) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069109-A1 | Therapeutic agents | TIE1, TEK, KDR | IDO1 3871/4885KDM4E 2006/4885TSHR 2363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.